Reni Benjamin
Stock Analyst at JMP Securities
(1.44)
# 3,288
Out of 4,843 analysts
189
Total ratings
38.61%
Success rate
-13.75%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $13.45 | - | 10 | May 15, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $26 → $22 | $8.22 | +167.64% | 14 | May 2, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.63 | +215.91% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.41 | +144.50% | 9 | Mar 31, 2025 | |
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $1.17 | +327.35% | 7 | Mar 14, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $65.06 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.72 | - | 5 | Mar 7, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Market Outperform | $125 | $101.35 | +23.33% | 21 | Mar 3, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $1.21 | +230.58% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.47 | +172.11% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $2.22 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.09 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.98 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.29 | +5,370.09% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $19.84 | -49.60% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $1.31 | - | 7 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.75 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $0.89 | +351.52% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $5.68 | +392.96% | 10 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $18.22 | +119.60% | 3 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $5 | $2.17 | +130.41% | 5 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.90 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $6.30 | +26.98% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $63.36 | -5.30% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $9.28 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $247.71 | +27.16% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $84.16 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $245.21 | +8.07% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $26.95 | - | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $2.74 | +520.44% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.38 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $8.84 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.38 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $35.11 | -65.82% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.24 | - | 1 | Nov 15, 2017 |
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $13.45
Upside: -
Bicycle Therapeutics
May 2, 2025
Maintains: Market Outperform
Price Target: $26 → $22
Current: $8.22
Upside: +167.64%
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.63
Upside: +215.91%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.41
Upside: +144.50%
Allogene Therapeutics
Mar 14, 2025
Upgrades: Market Outperform
Price Target: $5
Current: $1.17
Upside: +327.35%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $65.06
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.72
Upside: -
Blueprint Medicines
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $125
Current: $101.35
Upside: +23.33%
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.21
Upside: +230.58%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.47
Upside: +172.11%
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $2.22
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.09
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.98
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.29
Upside: +5,370.09%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $19.84
Upside: -49.60%
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.31
Upside: -
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.75
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $0.89
Upside: +351.52%
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $5.68
Upside: +392.96%
Apr 28, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $18.22
Upside: +119.60%
Mar 18, 2025
Upgrades: Market Outperform
Price Target: $5
Current: $2.17
Upside: +130.41%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.90
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $6.30
Upside: +26.98%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $63.36
Upside: -5.30%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $9.28
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $247.71
Upside: +27.16%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $84.16
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $245.21
Upside: +8.07%
Nov 4, 2024
Initiates: Market Perform
Price Target: n/a
Current: $26.95
Upside: -
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $2.74
Upside: +520.44%
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.38
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $8.84
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.38
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $35.11
Upside: -65.82%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $4.24
Upside: -